<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563482</url>
  </required_header>
  <id_info>
    <org_study_id>1670</org_study_id>
    <nct_id>NCT03563482</nct_id>
  </id_info>
  <brief_title>Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy.</brief_title>
  <official_title>Correlazione Dell'Imaging Metabolico Con l'Espressione Dei Marcatori Immunitari Nei Pazienti Con NSCLC Candidati All'Immunoterapia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to prospectively investigate the correlation between the&#xD;
      metabolic parameters on FDG-PET before and during immunotherapy treatment with the immune&#xD;
      infiltrate and other tissue or circulating markers in a NSCLC patients candidate to&#xD;
      immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional prospective study without medication lasting 36 months, including&#xD;
      an estimated period of 18 months for the enrolment and max 18 months of follow-up. All&#xD;
      consecutive patients affected by NSCLC and referred for immunotherapy with the anti-PD-1&#xD;
      agent nivolumab, or other checkpoint inhibitors that may become available in the future, will&#xD;
      be prospectively enrolled. The study cohort will consist of 40 patients.&#xD;
&#xD;
      All patients will undergo the following steps: 1) selection based on eligibility criteria and&#xD;
      informed consent; 2) baseline examinations (ceCT and 18F-FDG PET/CT); 3) tumor biopsy and&#xD;
      blood sampling; 4) Immunotherapy with check-point inhibitors; 5) response evaluation after 8&#xD;
      weeks of treatment (ceCT and 18F-FDG PET/CT) and second blood sampling; 6) follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate the tumor expression of immune markers with the metabolic characteristics on FDG-PET in patients with NSCLC candidates to immunotherapy.</measure>
    <time_frame>Baseline</time_frame>
    <description>Standardized uptake value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor expression of immune markers with the metabolic characteristics on FDG-PET in patients with NSCLC candidates to immunotherapy.</measure>
    <time_frame>Before treatment</time_frame>
    <description>Metabolic tumor burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate immune markers with the metabolic characteristics on FDG-PET in patients with NSCLC candidates to immunotherapy.</measure>
    <time_frame>Baseline</time_frame>
    <description>Tumor infiltrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the variation of metabolic parameters on FDG-PET in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Standardized uptake value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify the variation of metabolic parameters on FDG-PET in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Metabolic tumor burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate other tissue or circulating markers in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>Baseline</time_frame>
    <description>Tissue and blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate other tissue or circulating markers in patients with NSCLC before and 8 weeks after the first administration of immunotherapy.</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Tissue and blood samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlate all defined parameters with response to treatment and outcome</measure>
    <time_frame>18 months of follow up</time_frame>
    <description>Response assessment and disease outcome</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Positron-Emission Tomography</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biopsy and PET scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with pathological diagnosis of NSCLC eligible for immunotherapy;&#xD;
&#xD;
          -  obtained informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18 years;&#xD;
&#xD;
          -  pregnancy or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egesta Lopci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Castello A, Grizzi F, Toschi L, Rossi S, Rahal D, Marchesi F, Russo C, Finocchiaro G, Lopci E. Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2018 Jul;39(7):636-644. doi: 10.1097/MNM.0000000000000832.</citation>
    <PMID>29608508</PMID>
  </reference>
  <reference>
    <citation>Grizzi F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1072-1075. doi: 10.1007/s00259-018-3988-1. Epub 2018 Mar 12.</citation>
    <PMID>29532102</PMID>
  </reference>
  <reference>
    <citation>Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325. doi: 10.1007/s00259-017-3802-5. Epub 2017 Aug 16. Review.</citation>
    <PMID>28815334</PMID>
  </reference>
  <reference>
    <citation>Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.</citation>
    <PMID>27251642</PMID>
  </reference>
  <reference>
    <citation>Castello A, Toschi L, Rossi S, Mazziotti E, Lopci E. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. J Cancer Res Clin Oncol. 2020 May;146(5):1235-1243. doi: 10.1007/s00432-020-03150-9. Epub 2020 Feb 11.</citation>
    <PMID>32048008</PMID>
  </reference>
  <reference>
    <citation>Rossi S, Castello A, Toschi L, Lopci E. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy. 2018 Jul;10(9):797-805. doi: 10.2217/imt-2017-0187. Review.</citation>
    <PMID>30008262</PMID>
  </reference>
  <reference>
    <citation>Castello A, Lopci E. Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2. Q J Nucl Med Mol Imaging. 2019 Jun;63(2):150-158. doi: 10.23736/S1824-4785.19.03193-5. Epub 2019 Jul 8. Review.</citation>
    <PMID>31286751</PMID>
  </reference>
  <reference>
    <citation>Castello A, Rossi S, Mazziotti E, Toschi L, Lopci E. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of (18)F-FDG PET/CT. J Nucl Med. 2020 Jun;61(6):821-826. doi: 10.2967/jnumed.119.237768. Epub 2019 Dec 20.</citation>
    <PMID>31862803</PMID>
  </reference>
  <reference>
    <citation>Monterisi S, Castello A, Toschi L, Federico D, Rossi S, Veronesi G, Lopci E. Preliminary data on circulating tumor cells in metastatic NSCLC patients candidate to immunotherapy. Am J Nucl Med Mol Imaging. 2019 Dec 15;9(6):282-295. eCollection 2019.</citation>
    <PMID>31976158</PMID>
  </reference>
  <reference>
    <citation>Castello A, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L, Lopci E. Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors. Cancers (Basel). 2020 Feb 19;12(2). pii: E487. doi: 10.3390/cancers12020487.</citation>
    <PMID>32092983</PMID>
  </reference>
  <reference>
    <citation>Castello A, Lopci E. Update on tumor metabolism and patterns of response to immunotherapy. Q J Nucl Med Mol Imaging. 2020 Jun;64(2):175-185. doi: 10.23736/S1824-4785.20.03251-3. Epub 2020 Feb 27. Review.</citation>
    <PMID>32107904</PMID>
  </reference>
  <reference>
    <citation>Castello A, Rossi S, Toschi L, Mansi L, Lopci E. Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. Cancers (Basel). 2020 May 27;12(6). pii: E1373. doi: 10.3390/cancers12061373.</citation>
    <PMID>32471030</PMID>
  </reference>
  <reference>
    <citation>Castello A, Rossi S, Toschi L, Lopci E. Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1. Front Oncol. 2020 Jul 31;10:1090. doi: 10.3389/fonc.2020.01090. eCollection 2020.</citation>
    <PMID>32850315</PMID>
  </reference>
  <reference>
    <citation>Castello A, Lopci E. Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using (18)F-FDG PET/CT. J Nucl Med. 2020 Sep;61(9):1405. doi: 10.2967/jnumed.120.243444. Epub 2020 Mar 13.</citation>
    <PMID>32169909</PMID>
  </reference>
  <reference>
    <citation>Lopci E, Haanen JB. Cancer management in the era of immunotherapy: much more than meets the eye. Q J Nucl Med Mol Imaging. 2020 Jun;64(2):141-142. doi: 10.23736/S1824-4785.20.03252-5. Epub 2020 Feb 27.</citation>
    <PMID>32107905</PMID>
  </reference>
  <reference>
    <citation>Aide N, De Pontdeville M, Lopci E. Evaluating response to immunotherapy with (18)F-FDG PET/CT: where do we stand? Eur J Nucl Med Mol Imaging. 2020 May;47(5):1019-1021. doi: 10.1007/s00259-020-04702-4.</citation>
    <PMID>31996974</PMID>
  </reference>
  <reference>
    <citation>Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250. doi: 10.1007/s00259-018-4171-4. Epub 2018 Oct 5. Review.</citation>
    <PMID>30291373</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

